MedTrace Logo

Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam

NCT05001139 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-03-18

Study results available
· View outcomes & findings →

Summary

The scope of this open label clinical trial is to evaluate and confirm the performance of Relizema ecofoam in the improvement of the dermatitis severity. The disease severity will be clinically measured through the Investigator Global Assessment (IGA) after 28 days of treatment.

Conditions

  • Dermatitis

Interventions

DEVICE

Relizema ecofoam

DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration

Sponsors & Collaborators

  • Relife S.r.l.

    lead INDUSTRY

Principal Investigators

  • Giuseppe Micali · AOU Policlinico "G. Rodolico-San Marco" Catania

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2022-12-29
Completion
2023-06-15

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05001139 on ClinicalTrials.gov